Pilot study reveals promising results for planned Impella 5.5 support in complex heart surgeries.
Chicago, Illinois, 7 May 2026 – Johnson & Johnson has announced encouraging results from a new pilot study involving the planned use of its Impella 5.5 heart pump system in high-risk cardiac surgery patients. The findings highlight how advanced medical technology could improve recovery and reduce complications for patients with severe heart conditions.
The study, known as IMPACT, focused on patients undergoing major heart surgery while suffering from severe left ventricular dysfunction, a condition where the heart struggles to pump blood efficiently. These patients often face serious risks during and after surgery, including heart failure, kidney complications, and stroke.
The Impella 5.5 device is a small heart pump designed to support blood circulation during critical medical procedures. In this study, doctors used the device before patients were removed from cardiopulmonary bypass support during surgery. Researchers found that the planned use of the pump appeared safe and feasible, while also showing positive postoperative outcomes and low device-related complications.
The trial involved 100 high-risk cardiac surgery patients in the United States and was presented during the American Association for Thoracic Surgery annual meeting in Chicago. Medical experts believe the findings could open new possibilities for improving recovery in vulnerable heart patients.
Doctors involved in the study explained that proactive heart support may help reduce stress on the heart immediately after surgery. Instead of waiting for complications to occur, the planned use of the Impella system aims to provide early mechanical support during a critical stage of patient recovery.
The Impella 5.5 heart pump is already recognized in major cardiac care guidelines for treating postcardiotomy shock and low cardiac output syndrome. Researchers believe this latest study could help expand future research into preventive heart support strategies for surgical patients.
Johnson & Johnson also stated that several ongoing clinical studies are continuing to explore how Impella technology can support patients with heart failure, cardiogenic shock, and other serious cardiovascular conditions. The company remains focused on advancing heart recovery solutions through innovation and clinical research.
As cardiovascular diseases continue to rise worldwide, the demand for advanced cardiac support systems is also growing. Technologies like the Impella 5.5 may play an important role in improving patient outcomes, reducing surgical risks, and supporting the future of modern heart care.
